A healthtech device can pass every lab test, hit every performance benchmark, and still fail in the market. Not because the underlying technology was wrong but because of what happened in the space between the lab bench and the person actually using it at home, under real conditions, without a technician standing by. Across the medtech and healthtech device work we do; this is the pattern that shows up again and again. The products that succeed and the products that struggle

A scientist in protective gear uses a pipette for precise liquid measurement in a busy laboratory setting. High capital intensity is one of the most consistently cited challenges facing India's biotech sector, and it's a real constraint, not an excuse founders invent. Syngene's own industry analysis is blunt about the underlying economics: outsourcing to an established CRDMO delivers roughly 90% faster startup time, 70-80% lower workforce cost, and 85% lower infrastructure se

Every health, wellness, or nutraceutical founder eventually faces the same tension: the claim that would sell the most product is often not the claim that's legally defensible. Getting this wrong doesn't just risk a warning letter — it risks the credibility your entire brand is built on, in a category where credibility is the actual product. India's regulatory landscape for health claims sits across three main bodies and understanding how they interact is the first step to bu

India's clinical trial regulation is, by design, one of the clearer parts of the drug development pathway but preclinical research doesn't get the same treatment. The New Drugs and Clinical Trials Rules, 2019 were explicitly built to make clinical trial regulation unambiguous and foreseeable, clear documentation requirements, clear committee structures, clear expectations at every phase. Founders and CROs alike can point to exactly what's required and when. However, the gap b

India has built genuine manufacturing strength in various industries over the last decade: electronics, medtech, FMCG, consumer goods broadly. Government policy has pushed hard in this direction, and it's working. But a pattern keeps showing up across the companies we work with, regardless of category: the country is manufacturing at scale without owning enough of the design. It's a subtle gap, and it's expensive precisely because it's subtle. Nothing about it shows up as an

India's nutraceutical market is now worth close to $9 billion, and depending on whose forecast you trust, it's on track to hit somewhere between $23 billion and $30 billion within the next six to eight years. That kind of growth usually triggers a predictable response from large FMCG players: build a competing product, lean on distribution muscle, and out-scale the smaller brands. That's not what's happening this time. Instead, some of India's largest FMCG companies have been

Launching or scaling a product is a complex challenge. You face tough decisions every day. What features should you build? Which customer needs matter most? How do you avoid costly mistakes? The answer lies in one powerful tool: data. Using data insights can transform your product strategy from guesswork into a clear, evidence-based plan. Data helps you understand your market, your customers, and your product’s performance. It reveals what works and what doesn’t. It guides